Searched for
CARDIAC DRUGS MARKET
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
- Cardiac drugs log highest sales in 2025 as NCD cases surgeHeart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with...
- India's pharmaceutical market posts 10% growth in OctoberThe revival was on the back of therapies, including cardiac and anti-diabetic, which grew by 19.5% and 9.7% respectively in October (over S...
- Drug sales reveal our lifestyle woesIndians spent over Rs 1,36,000 cr on medicines in last one year ending September 2019. People spent over Rs 17,000 cr on cardiac drugs, aro...
- Zydus Cadila gets USFDA nod for cardiac drugThe product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said in a statement.
- "Indian drug regulator wants patients to report adverse effects of Abbott BVS"BVS used as an implant during an angioplasty procedure is a tube device that clears blockages in arteries that carry blood to the heart whi...
- Revision in National List of Essential Medicines to help save up to 20%The overall coverage of new medicines being added to the NLEM will be nearly Rs 8,000 crore in the organized pharma retail market.
- Product recall may spell trouble for Sun Pharma's US arm reviewOne of the products recall in the world’s largest drug market by the US arm of Sun Pharma, India’s largest drugmaker by market capitalisati...
- Drug recall to have minimal impact on SunIndia’s largest drugmaker by market capitalisation Sun Pharma whose US arm recalled one of the products sold in the world’s largest drug ma...
Load More
